

**Supplementary Material**

**Antibacterial and Immunosuppressive Effects of a Novel Marine Brown  
Algae-Derived Ester in Atopic Dermatitis**


## Contents of Figures

<b>Figure S1:</b> Schematic representation of the extraction of biologically active fractions .....	4
<b>Figure S2:</b> Separation of fractions from <i>H. fusiformis</i> EA fraction using Prep-HPLC.....	4
<b>Figure S3:</b> TLC analysis results of <i>Hizikia</i> EA fraction using silica gel chromatography fractions .....	5
<b>Figure S4:</b> $^1\text{H}$ NMR of HSN-S1 in DMSO- $d_6$ .....	6
<b>Figure S5:</b> $^{13}\text{C}$ NMR of HSN-S1 in DMSO- $d_6$ .....	6
<b>Figure S6:</b> DEPT-90 of HSN-S1 in DMSO- $d_6$ .....	7
<b>Figure S7:</b> DEPT-135 of HSN-S1 in DMSO- $d_6$ .....	7
<b>Figure S8:</b> HSQC of HSN-S1 in DMSO- $d_6$ .....	8
<b>Figure S9:</b> COSY of HSN-S1 in DMSO- $d_6$ .....	8
<b>Figure S10:</b> HMBC of HSN-S1 in DMSO- $d_6$ .....	9
<b>Figure S11:</b> $^1\text{H}$ NMR of mannitol standard in D <sub>2</sub> O .....	9
<b>Figure S12:</b> $^1\text{H}$ NMR of the HSN-S1 sugar alcohol in D <sub>2</sub> O .....	10


## **Contents of Tables**

<b>Table S1:</b> Results of cytotoxicity analysis on HSN-S1 .....	11
<b>Table S2:</b> HPLC gradient elution conditions for <i>H. fusiformis</i> EA fraction.....	11
<b>Table S3:</b> Effect of different subfractions separated from <i>H. fusiformis</i> on the production of IL-2 in anti-CD3ε-induced splenocytes and expression of NF-κB in LPS-induced THP-1 Lucia™ NF-κB cells .....	11
<b>Table S4:</b> Elution conditions for silica gel open column chromatography (A) and Prep-HPLC gradient elution (B) for purification of anti-AD compounds.....	12
<b>Table S5:</b> Primer sequences for quantitative reverse transcription polymerase chain reaction.....	13


Supplementary data




**Figure S1:** Schematic representation of the extraction of biologically active fractions.




**Figure S2:** Separation of fractions from *H. fusiformis* EA fraction using Prep-HPLC. "Drain section" refers to areas where no peak is detected during the washing phase.




**Figure S3:** TLC analysis results of *Hizikia* EA fraction using silica gel chromatography fractions.




**Figure S4:**  $^1\text{H}$  NMR of HSN-S1 in  $\text{DMSO}-d_6$ .




**Figure S5:**  $^{13}\text{C}$  NMR of HSN-S1 in  $\text{DMSO}-d_6$ .




**Figure S6:** DEPT-90 of HSN-S1 in  $\text{DMSO}-d_6$ .




**Figure S7:** DEPT-135 of HSN-S1 in  $\text{DMSO}-d_6$ .




**Figure S8:** HSQC of HSN-S1 in  $\text{DMSO}-d_6$ .




**Figure S9:** COSY of HSN-S1 in  $\text{DMSO}-d_6$ .



**Figure S10:** HMBC of HSN-S1 in  $\text{DMSO}-d_6$ .



**Figure S11:**  $^1\text{H}$  NMR of mannitol standard in  $\text{D}_2\text{O}$ .



**Figure S12:**  $^1\text{H}$  NMR of the HSN-S1 sugar alcohol in  $\text{D}_2\text{O}$ .

**Table S1:** Results of cytotoxicity analysis on HSN-S1.

Cell	Dose range for cell treatment ( $\mu\text{g/mL}$ )	$\text{CC}_{50}$ ( $\mu\text{g/mL}$ )	Remarks
HaCaT	1.0 to 100.0	$24.2 \pm 0.1$	
RAW264.7	1.0 to 100.0	$54.4 \pm 1.8$	
Splenocytes	1.0 to 100.0	$62.8 \pm 0.2$	
Naïve CD4 <sup>+</sup> Th	1.0 to 100.0	> 100	
Jurkat	1.0 to 100.0	$50.3 \pm 0.1$	
RBL-2H3	0.3 to 100	$14.6 \pm 0.4$	
Jurkat Lucia-NFAT	1.0 to 100.0	$57.9 \pm 2.8$	Luciferase activity of transfected cells

**Table S2:** HPLC gradient elution conditions for *H. fusiformis* EA fraction.

Time (min)	Flow (mL/min)	% D.W.	% ACN
0.0	1.0	100.0	0.0
53.0	1.0	0.0	100.0
58.0	1.0	0.0	100.0
60.0	1.0	100.0	0.0

D.W: distilled water, ACN: acetonitrile.

**Table S3:** Effect of different subfractions separated from *H. fusiformis* on the production of IL-2 in anti-CD3ε-induced splenocytes and expression of NF-κB in LPS-induced THP-1 Lucia<sup>TM</sup> NF-κB cells.

Fraction No	Splenocytes (% of Anti-CD3ε group)	THP-1 NFκB (% of LPS group)
F1	$48.13 \pm 0.01$	$36.03 \pm 0.63$
F2	$39.05 \pm 0.66$	$71.34 \pm 0.19$
<b>F3</b>	<b><math>30.53 \pm 0.15</math></b>	<b><math>20.48 \pm 0.38</math></b>
F4	$39.34 \pm 2.04$	$80.77 \pm 0.48$
F5	$65.69 \pm 4.09$	$31.24 \pm 0.10$
F6	$45.24 \pm 3.76$	$84.10 \pm 0.30$
F7	$54.63 \pm 6.29$	$84.07 \pm 0.32$
F8	$75.06 \pm 8.15$	$76.69 \pm 0.94$
F9	$106.55 \pm 4.11$	$61.46 \pm 0.57$
F10	$61.22 \pm 2.63$	$80.26 \pm 0.87$

**Table S4:** Elution conditions for silica gel open column chromatography (A) and Prep-HPLC gradient elution (B) for purification of anti-AD compounds.

(A)

Fraction No	Solvent	BV
OCF1	DCM	2.5
OCF2	DCM:EA=1:1	2.5
OCF3	EA	2.5
OCF4-1	DCM:MeOH=7:1	2.5
OCF4-2	DCM:MeOH=7:1	2.5
OCF5 (wash)	MeOH	2.5

BV: bed volume, DCM: dichloromethane, EA: ethyl acetate, and MeOH: methanol.

(B)

Time (min)	Flow (mL/min)	% D.W	% ACN
0.0	1.0	50.0	50.0
53.0	1.0	0.0	100.0
58.0	1.0	0.0	100.0
60.0	1.0	50.0	50.0

D.W: distilled water and ACN: acetonitrile.

**Table S5:** Primer sequences for quantitative reverse transcription polymerase chain reaction.

Species	Gene	Direction	Sequence (5' to 3')	Accession
Human	TNF- $\alpha$	Forward	5'- CTC TTC TCC TTC CTG ATC GT	NM_000594.4
		Reverse	5'- CTG GTT ATC TCT CAG CTC CA	
	MCP-1	Forward	5'- TAG AAG AAT CAC CAG CAG CA	NM_002982.4
		Reverse	5'- GTC TTC GGA GTT TGG GTT TG	
	CXCL10	Forward	5'- CTA AGT GGC ATT CAA GGA GT	NM_001565.4
		Reverse	5'- AGA CCT TTC CTT GCT AAC TG	
	$\beta$ -actin	Forward	5'- ACC TGA CTG ACT ACC TCA TG	NM_001101.5
		Reverse	5'- CTC ATT GCC AAT GGT GAT GA	
Mouse	IL-1 $\beta$	Forward	5'- CTG TGT AAT GAA AGA CGG CA	NM_008361.4
		Reverse	5'- TAT GTC CTG ACC ACT GTT GT	
	IL-2	Forward	5'- CAC TTC AAG CTC CAC TTC AA	NM_008366.3
		Reverse	5'- AGT CAA ATC CAG AAC ATG CC	
	IL-4	Forward	5'- TGA GAG AGA TCA TCG GCA TT	NM_021283.2
		Reverse	5'- TGA TGT GGA CTT GGA CTC AT	
	IL-9	Forward	5'- TGA CAT ACA TCC TTG CCT CT	NM_008373.2
		Reverse	5'- AGT CTT GAT TTC TGT GTG GC	
	IL-10	Forward	5'- ACA ATA ACT GCA CCC ACT TC	NM_010548.2
		Reverse	5'- CCA CTG CCT TGC TCT TAT TT	
	IL-13	Forward	5'- TCT GAC CCT TAA GGA GCT TA	NM_008355.3
		Reverse	5'- TAC AGA GGC CAT GCA ATA TC	
	IL-17A	Forward	5'- CTC CAG AAT GTG AAG GTC AA	NM_010552.3
		Reverse	5'- AAC AGA ATT CAT GTG GTG GT	
	IL-21	Forward	5'- CCT GAA CTT CTA TCA GCT CC	NM_021782.3
		Reverse	5'- ATC ACA GGA AGG GCA TTT AG	
	IL-22	Forward	5'- CTC CCC CAG TCA GAC AGG TT	NM_016971.2
		Reverse	5'- AAA CAG CAG GTC CAG TTC CC	
	IL-33	Forward	5'- CTG TTG ACA CAT TGA GCA TC	NM_001360725.1
		Reverse	5'- CCA GAT GTC TGT GTC TTT GA	
	COX-2	Forward	5'- CGA TGT CAT GGA ACT GTA CC	NM_011198.5
		Reverse	5'- ATC TTA AAA CCC ACT TCG CC	
	GATA3	Forward	5'- TCG TAC ATG GAA GCT CAG TA	XM_030247533.2
		Reverse	5'- AAG AGA TGA GGA CTG GAG TG	
	$\beta$ -actin	Forward	5'-CAT CAA AGA GAA GCT GTG CT	NM_007393.5
		Reverse	5'-GAA GGA AGG CTG GAA AAG AG	